Term ends Feb 8, 2038 · Low confidence
20-year base term ends Feb 8, 2038
Held by Abelzeta Inc.
Filed Jun 3, 2022 as application 17/831,637 · Granted Mar 24, 2026
Base term plus 759 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2018
2038
Clock starts
Feb 8, 2018
Feb 8, 2018
Term ends
Feb 8, 2038
Feb 8, 2038
Granted
Mar 24, 2026
Mar 24, 2026
base term
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
759
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 11,066,457, US 11,472,858, US 11,608,369, US 11,618,778, US 12,747,279.
0 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 759 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 0 of 2 maintenance fees are paid so far. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Feb 8, 2018, when application PCT/CN2018/075867, the earliest non-provisional in its chain, was filed (this one was filed Jun 3, 2022); a parent in its chain could not be resolved (the next row) | Feb 8, 2038 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +759 days, USPTO patent term adjustment record | Mar 8, 2040 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 11,066,457, US 11,472,858, US 11,608,369, US 11,618,778, US 12,747,279) | capped to Feb 8, 2038 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 2 maintenance fees paid | In force | High confidence |
| Further caveats on record | The record names parents not resolved: 16484482, 16484482 | Low confidence overall | Low confidence |
| Computed term end | The steps above, in order | Feb 8, 2038 | Low confidence |
This family
| US 11,066,457 | In force Feb 2038 | Feb 2038 |
| US 11,472,858 | In force Feb 2038 | Feb 2038 |
| US 11,618,778 | In force Feb 2038 | Feb 2038 |
| US 11,608,369 | In force Feb 2038 | Feb 2038 |
| US 12,583,903 | this patent Feb 2038 | Feb 2038 |
| US 12,747,279 | In force Feb 2038 | Feb 2038 |
| Application 18/263,050 | Pending not computed | not computed |
7 of 9 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 3, 2022 Reel 60099, frame 363 | Yao, Yihong; Huang, Jiaqi; Zhu, Shigui; Zhu, Wei; Yao, Xin; Li, Zhiyuan; Zhang, Li; Zhu, Lin; Ma, Anyun; Wei, Yutian; Li, Yanfeng; Wang, Qingxia; He, Jiaping | Cellular Biomedicine Group (Shanghai) Ltd.; Cellular Biomedicine Group (Wuxi) Ltd. | Assignment of Assignor's Interest |
| Jun 3, 2022 Reel 60099, frame 458 | Cellular Biomedicine Group (Shanghai) Ltd. | Cellular Biomedicine Group HK Limited | Assignment of Assignor's Interest |
| Jun 3, 2022 Reel 60099, frame 542 | Cellular Biomedicine Group (Wuxi) Ltd. | Cellular Biomedicine Group HK Limited | Assignment of Assignor's Interest |
| Jun 3, 2022 reel/frame not recorded | He, Jiaping; Huang, Jiaqi; Li, Yanfeng; Li, Zhiyuan; Ma, Anyun; Wang, Qingxia; Wei, Yutian; Yao, Xin; Yao, Yihong; Zhang, Li; Zhu, Lin; Zhu, Shigui; Zhu, Wei | Cellular Biomedicine Group (Shanghai) Ltd. | Assignment of Assignor's Interest |
| Jun 3, 2022 reel/frame not recorded | He, Jiaping; Huang, Jiaqi; Li, Yanfeng; Li, Zhiyuan; Ma, Anyun; Wang, Qingxia; Wei, Yutian; Yao, Xin; Yao, Yihong; Zhang, Li; Zhu, Lin; Zhu, Shigui; Zhu, Wei | Cellular Biomedicine Group (Wuxi) Ltd. | Assignment of Assignor's Interest |
| Dec 15, 2022 Reel 62105, frame 405 | Cellular Biomedicine Group HK Ltd. | Cellular Biomedicine Group Inc. | Assignment of Assignor's Interest |
| Jan 19, 2024 Reel 66356, frame 108 | Cellular Biomedicine Group, Inc. | Abelzeta Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Feb 2038
Term ends Feb 8, 2038. Maintenance fees still fall due before then
Note
The 759 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 11,066,457, US 11,472,858, US 11,608,369, US 11,618,778, US 12,747,279.
Citations
We have no citation count for this patent yet. That is not the same as never having been cited.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.